AIDS Treatment News logo      

June 9, 2010

Myriad Genetics Suspends Its HIV Maturation Inhibitor Program

AIDSmeds.com: "Myriad Genetics announced it is suspending its HIV drug development program and will focus instead on oncology drugs. The company says it is taking this step “for strategic, business reasons; and a reduction in workforce.”

Myriad had been developing a maturation inhibitor called bevirimat (MPC-4326, PA-457) since 2009, after purchasing the rights to the drug from Panacos Pharmaceuticals."

0 comments: